Search research articles
Contact Us
Filters
Showing results (81-90 of 111) with videos related to
Page
of 12
Sort By:
Acta Dermato-Venereologica
|
October 3, 2025
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations
Niccolo Gori, Alvise Sernicola, Elena Ippoliti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 29, 2024
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series
Niccolò Gori, Elena Ippoliti, Silvia Mariel Ferrucci, et al.
Frontiers in Immunology
|
April 27, 2026
Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy
Martina Morelli, Giovanni Luca Scaglione, Anna Dattolo, et al.
The Journal of Dermatological Treatment
|
February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)
Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Clinical Medicine
|
July 13, 2024
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study
Marco Galluzzo, Emanuele Trovato, Marina Talamonti, et al.
The Journal of Dermatological Treatment
|
November 3, 2025
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors
Niccolò Gori, Lucia Di Nardo, Elena Ippoliti, et al.
Dermatology Practical & Conceptual
|
March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Dermatology and Therapy
|
January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study
Federico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
The Journal of Dermatological Treatment
|
July 4, 2023
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study
Niccolò Gori, Alvise Sernicola, Ersilia Tolino, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 111) with videos related to
Sort By:
Page
of 12
Acta Dermato-Venereologica
|
October 3, 2025
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations
Niccolo Gori, Alvise Sernicola, Elena Ippoliti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 29, 2024
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series
Niccolò Gori, Elena Ippoliti, Silvia Mariel Ferrucci, et al.
Frontiers in Immunology
|
April 27, 2026
Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy
Martina Morelli, Giovanni Luca Scaglione, Anna Dattolo, et al.
The Journal of Dermatological Treatment
|
February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)
Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Clinical Medicine
|
July 13, 2024
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study
Marco Galluzzo, Emanuele Trovato, Marina Talamonti, et al.
The Journal of Dermatological Treatment
|
November 3, 2025
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors
Niccolò Gori, Lucia Di Nardo, Elena Ippoliti, et al.
Dermatology Practical & Conceptual
|
March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Dermatology and Therapy
|
January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study
Federico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
The Journal of Dermatological Treatment
|
July 4, 2023
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study
Niccolò Gori, Alvise Sernicola, Ersilia Tolino, et al.
Page
of 12